Emily Cutting - Ataxia UK - Page 2

Emily Cutting

New research suggests a reason for a delayed age of onset in some people with Friedreich’s ataxia: Full interview with researcher Dr Suran Nethisinghe

The Ataxia Magazine Issue 215 reported on a new paper on Friedreich’s ataxia (FA) from the team led by Professor Paola Giunti at the London Ataxia Centre, which has been

New research suggests a reason for a delayed age of onset in some people with Friedreich’s ataxia: Full interview with researcher Dr Suran Nethisinghe Read More »

US FDA and European Commission grants VICO Therapeutics Orphan Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia 

Spinocerebellar ataxias (SCAs) are a group of rare, progressive hereditary genetic disorders that affects the cerebellum, brain stem and spinal cord. Currently, more than 30 types of SCAs have been identified. SCAs are caused by genetic mutations,

US FDA and European Commission grants VICO Therapeutics Orphan Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia  Read More »

New Ataxia Consortium created to accelerate the development of treatments for the Ataxias

Ataxia UK, along with Ataxia Global Initiative and National Ataxia Foundation, recently partnered with Critical Path Institute (C-Path) for the launch of their Critical Path to Therapeutics for the Ataxias

New Ataxia Consortium created to accelerate the development of treatments for the Ataxias Read More »

Donate Now
Scroll to Top